Prostate Cancer

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Targeted Oncology interviewed Cy Stein, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology and deputy director of Clinical Research at City of Hope National Medical Center.

A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with mCRPC, a recent analysis of the phase III COU-AA-30 pivotal trial demonstrated.

Evan Y. Yu, MD, discusses the role of PET imaging in prostate cancer.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

William Kevin Kelly, DO, discusses the role of chemotherapy in castration-resistant prostate cancer.

An interview with James Mohler, MD, associate director and senior vice president for Translational Research at Roswell Park Cancer Institute, Buffalo, NY, and chair of the NCCN Guidelines Panel for Prostate Cancer.

Over the past three years, diverse new therapies have been approved to treat advanced prostate cancer, including agents that have shown some promise in delaying its progression to the bone.

Targeted Oncology spoke with Padmanee Sharma, MD, PhD, about advances in immunotherapy for castration-resistant prostate cancer (CRPC).

Leonard G. Gomella, MD, FACS, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer.

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

A phase III trial examining the anti-CTLA-4 immune checkpoint inhibitor ipilimumab (Yervoy) in men with metastatic castration-resistant prostate cancer (mCRPC) failed to meet its primary endpoint of prolongation in overall survival (OS).

Amid a flurry of new drug approvals in recent years, the American Urological Association (AUA) has issued its first set of guidelines for the management of patients with metastatic castration-resistant prostate cancer (mCRPC).

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

James L. Gulley, MD, PhD, discusses how PROSTVAC works in patients with castration-resistant prostate cancer.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Long-term safety and efficacy results from COU-AA-302 in mCRPC, and efficacy and safety data for enzalutamide monotherapy were among the ASCO 2013 Annual Meeting presentations that extended clinically useful information for the care of patients with prostate cancer.

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CELLSEARCH® CTC Test, which allows for an assessment of patient prognosis.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Neal D. Shore, MD, FACS, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.

Three presentations from the ASCO 2013 Annual Meeting extended positive findings comparing nab-paclitaxel and gemcitabine to gemcitabine in 861 untreated patients with advanced pancreatic cancer.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.